Alkermes plc (ALKS) Report Analysis
Corporate Events
Alkermes plc Presents at Goldman Sachs 43rd Annual Global Healthcare Conference, Jun-15-2022 02:40 PM
2022-06-08 20:00:00
Alkermes plc Presents at Goldman Sachs 43rd Annual Global Healthcare Conference, Jun-15-2022 02:40 PM. Venue: Terranea Resort, Rancho Palos Verdes, California, United States.
Alkermes Solicits Proxies from Shareholders
2022-06-06 17:30:00
On June 6, 2022, Alkermes plc filed a definitive proxy statement soliciting proxies and urged the shareholders to for the election of 4 Class II directors, Emily Peterson Alva, Cato T. Laurencin, Brian P. McKeon, and Christopher I. Wright, to serve on the Company’s Board of Directors from those individuals validly nominated by the Board or by any shareholder of the Company for election at the annual meeting in accordance with the Company’s articles of association.
Alkermes plc Presents at 2022 Jefferies Global Healthcare Conference, Jun-08-2022 02:30 PM
2022-06-01 20:00:00
Alkermes plc Presents at 2022 Jefferies Global Healthcare Conference, Jun-08-2022 02:30 PM. Venue: Marriott Marquis, New York City, New York, United States.
Alkermes plc Presents ARTISTRY-1 Data At 2022 American Society of Clinical Oncology Annual Meeting
2022-06-01 11:00:00
Alkermes plc announced plans to present data from the ARTISTRY-1 clinical trial for nemvaleukin alfa (nemvaleukin), the company's novel, investigational, engineered interleukin-2 (IL-2) variant immunotherapy. The data will be presented in an oral presentation at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place June 3-7, 2022 in Chicago and virtually, and in an investor webcast hosted by the company on June 6, 2022. The presentations will include efficacy and safety data from ARTISTRY-1, a phase 1/2 study evaluating the safety, tolerability and efficacy of nemvaleukin administered intravenously as a monotherapy and in combination with pembrolizumab (KEYTRUDA®). In this study, nemvaleukin demonstrated anti-tumor activity with durable responses as monotherapy in checkpoint inhibitor (CPI)-experienced melanoma and renal cell carcinoma (RCC) patients and as combination therapy in pretreated patients across a range of difficult-to-treat tumors, including in tumor types where CPIs have had limited clinical benefit, and in CPI-experienced patients. Treatment-related adverse events (AEs) were mostly transient and manageable. Data highlights from the ASCO oral presentation and the company's investor presentation include the following (all data are as of the Oct. 29, 2021 ASCO data cutoff date, unless otherwise noted): The ARTISTRY-1 monotherapy cohorts included heavily pretreated, CPI-experienced patients with advanced melanoma or RCC. Melanoma monotherapy cohort (46 evaluable patients): Six patients achieved a partial response (PR), of which three were confirmed. Two of the six PRs were reported after the ASCO data cutoff date. Stable disease (SD) was observed in 31 patients. All melanoma patients who achieved a PR with nemvaleukin monotherapy had previously progressed on CPI treatment. Out of six evaluable mucosal melanoma patients, two patients achieved a PR (one confirmed). One of these two patients who achieved a PR remained on nemvaleukin monotherapy for more than two years, with a duration of response (DOR) of 79 weeks. RCC monotherapy cohort (22 evaluable patients): Four patients achieved a PR, of which three were confirmed. Three of the patients who achieved a PR remained on nemvaleukin monotherapy for a range of 24 – 63 weeks. SD was observed in 10 patients. All RCC patients who achieved a PR with nemvaleukin monotherapy had previously progressed on CPI treatment. The ARTISTRY-1 combination cohorts included patients with PD-1/L1 unapproved tumor types; patients with PD-1/L1 approved tumor types (PD-1/L1 pretreated and PD-1/L1 treatment naïve) as well as tumor-specific cohorts and a cohort for patients who rolled over into a combination cohort from a monotherapy cohort. Among the 137 total evaluable patients, four complete responses (CRs) and 18 PRs were observed, SD was observed in 60 patients, and overall median DOR was 23 weeks. In the PD-1/L1 unapproved cohort (36 evaluable patients): Two patients achieved a CR, four patients achieved a PR and SD was observed in 14 patients. Both of these CRs and two of these PRs (one confirmed), were in patients with platinum-resistant ovarian cancer (PROC) (out of 14 evaluable PROC patients in this cohort). Median DOR in the PROC cohort was 53 weeks. In the PD-1/L1 approved cohorts (total 43 evaluable patients): Among 22 evaluable pretreated patients, one patient achieved a PR and SD was observed in 10 patients. Among 21 evaluable PD-1/L1 naïve patients, one patient achieved a CR, six patients achieved PRs and SD was observed in seven patients. Treatment-related adverse events (TRAEs) across the ARTISTRY-1 study were consistent with those previously reported for the IV nemvaleukin monotherapy and combination therapy-treated populations from the trial. Pyrexia, chills and neutropenia/decreased neutrophil count were the most commonly reported TRAEs. Across the ARTISTRY-1 study, nemvaleukin in combination with pembrolizumab demonstrated no additive toxicity compared to pembrolizumab alone and no event of capillary leak syndrome was reported. Trial-in-progress posters from the ongoing ARTISTRY-3 trial and the potential registration-enabling ARTISTRY-6 and ARTISTRY-7 trials will also be presented at the ASCO meeting.
Alkermes plc - Shareholder/Analyst Call
2022-06-01 11:00:00
To discuss data from the ARTISTRY-1 clinical trial and the ARTISTRY clinical program
Alkermes plc Announces Management Changes
2022-05-26 21:36:00
Alkermes plc announced appointment of Dr. Christopher I. Wright, M.D., Ph.D. to the Board on May 24, 2022. Dr. Wright is a highly accomplished scientific and medical leader with nearly three decades of drug development and clinical expertise in diseases of the central nervous system. Dr. Wright currently serves as Chief Medical Officer at AavantiBio Inc. and previously served in senior medical and clinical roles at Cyclerion Therapeutics Inc., Ironwood Pharmaceuticals Inc., Axcella Health Inc., and Vertex Pharmaceuticals Incorporated, where he oversaw the development of ORKAMBI® and KALYDECO®. In addition to his industry experience, Dr. Wright brings more than 20 years of experience as both a practicing, board-certified neurologist at Brigham and Women's Hospital in Boston and as an Associate Professor of Neurology at Harvard Medical School. As part of the Board's continued refreshment process, Nancy J. Wysenski has been appointed as Lead Independent Director, effective as of the close of the Annual Meeting. Two longer-serving directors, David W. Anstice AO, the company's current Lead Independent Director, and Wendy L. Dixon, Ph.D., will retire from the Board at the close of the Annual Meeting. With the appointment announced, the Board has appointed seven new independent directors since 2019, including three in the last year alone, further strengthening its expertise in targeted areas of importance. Each of the new directors appointed to the Board is independent and has no previous connections to the company or its leadership team. In addition, five longer-serving directors have retired over the course of the past three years. As a result of these significant board refreshment activities, the Board has increased the diversity of its membership and has reduced the average director tenure from approximately six years as of June 30, 2019 to approximately three years as of the close of the upcoming Annual Meeting. The recent additions to the Board include three directors appointed with the support of Elliott Investment Management L.P. — Emily Peterson Alva in May 2021, and David A. Daglio and Brian P. McKeon in December 2020 — as well as a director designated by Sarissa Capital Management (together with its affiliates, Sarissa) — Cato T. Laurencin, M.D., Ph.D. in November 2021. Dr. Wright currently serves as the Chief Medical Officer of AavantiBio Inc., a Cambridge, Mass.-based company focused on developing precision gene therapies for the treatment of debilitating diseases. Prior to joining AavantiBio, Dr. Wright served as Senior Vice President, Chief Medical Officer of Cyclerion Therapeutics Inc. (Cyclerion), where he led global development functions across therapeutic areas, and prior to that served as Senior Vice President, Chief Development Officer of Ironwood Pharmaceuticals Inc. Earlier in his career, Dr. Wright served as Senior Vice President, Chief Medical Officer of Axcella Health Inc. and Senior Vice President of Global Medicines Development and Affairs at Vertex Pharmaceuticals Incorporated (Vertex), where he led global development functions across therapeutic areas, including clinical development and operations, regulatory and medical affairs, and pharmacovigilance. In his role at Vertex, Dr. Wright directly oversaw the successful submission of medications for approval to the FDA, EMA and other regulatory bodies. Dr. Wright currently serves as a Scientific Advisor for Cyclerion. Dr. Wright was an Associate Professor of Neurology at Harvard Medical School and a practicing, board-certified neurologist at Brigham and Women's Hospital for 20 years. Dr. Wright earned his A.B., Magna Cum Laude, in Biochemical Sciences from Harvard University and his M.D., Magna Cum Laude, in Medicine and Neuroscience from Harvard Medical School. Later, he earned his Ph.D. in Neuroanatomy from Vrije Universiteit and his MMSc. in Clinical Investigation from Harvard Medical School.
Alkermes Solicits Proxies from Shareholders
2022-05-26 17:29:00
On May 26, 2022, Alkermes plc announced that Sarissa Capital Management LP has notified the Company that it intends to nominate 2 director candidates for election at the annual meeting. The Company filed a preliminary proxy statement soliciting proxies and urged the shareholders to vote for the election of its nominees, Emily Peterson Alva, Cato T. Laurencin, Brian P. McKeon, and Christopher I. Wright, as directors of the Company on the Company’s proxy card at the annual shareholders meeting.
Alkermes plc Announces Four Abstracts Accepted for Presentation At the 2022 American Society of Clinical Oncology Annual Meeting
2022-05-09 11:00:00
Alkermes plc announced the acceptance of four abstracts related to nemvaleukin alfa (nemvaleukin), the company's novel, investigational, engineered interleukin-2 (IL-2) variant immunotherapy, at the American Society of Clinical Oncology (ASCO) Annual Meeting, taking place June 3-7, 2022 in Chicago and virtually. The final dataset from the phase 1/2 ARTISTRY-1 clinical trial, evaluating the safety, tolerability and efficacy of nemvaleukin administered intravenously as a monotherapy and in combination with pembrolizumab (KEYTRUDA), will be shared in an oral presentation. In addition, trial-in-progress posters from the ongoing ARTISTRY-3 trial and the potential registration-enabling studies ARTISTRY-6 and ARTISTRY-7 will be presented.
Alkermes plc Presents at The 2022 ASCO Annual Meeting, Jun-04-2022 01:15 PM
2022-05-09 11:00:00
Alkermes plc Presents at The 2022 ASCO Annual Meeting, Jun-04-2022 01:15 PM. Venue: McCormick Place, Chicago, Illinois, United States.
Alkermes plc Presents at Professional Society for Health Economics and Outcomes Research Annual Meeting, May-15-2022
2022-05-02 11:00:00
Alkermes plc Presents at Professional Society for Health Economics and Outcomes Research Annual Meeting, May-15-2022 . Speakers: Craig C. Hopkinson, Executive VP of Research & Development and Chief Medical Officer.
American Society Of Clinical Psychopharmacology Inc, American Society of Clinical Psychopharmacology 2022 Annual Meeting, May 31, 2022 through Jun 03, 2022
2022-05-02 11:00:00
American Society Of Clinical Psychopharmacology Inc, American Society of Clinical Psychopharmacology 2022 Annual Meeting, May 31, 2022 through Jun 03, 2022. Venue: Scottsdale, Ariz, Scarsdale, United States.
Alkermes plc Presents at American Society of Clinical Psychopharmacology 2022 Annual Meeting, May-31-2022 05:05 PM
2022-05-02 11:00:00
Alkermes plc Presents at American Society of Clinical Psychopharmacology 2022 Annual Meeting, May-31-2022 05:05 PM. Venue: Scottsdale, Ariz, Scarsdale, United States. Speakers: Craig C. Hopkinson, Executive VP of Research & Development and Chief Medical Officer.
Alkermes plc Reiterates Financial Guidance for the Year Ending December 31, 2022
2022-04-27 11:08:00
Alkermes plc reiterated financial guidance for the year ending December 31, 2022. For the period, the company expects revenues of $1,000 million to $1,090 million, GAAP Net Loss of $180 million to $210 million and GAAP Net Loss Per Share of $1.10 to $1.29.
Alkermes plc to Report Q1, 2022 Results on Apr 27, 2022
2022-04-23 17:15:00
Alkermes plc announced that they will report Q1, 2022 results on Apr 27, 2022
Alkermes plc, Q1 2022 Earnings Call, Apr 27, 2022
2022-04-20 20:00:00
Alkermes plc, Q1 2022 Earnings Call, Apr 27, 2022
Alkermes plc Commences Arbitration Related to License Agreements with Janssen Pharmaceutica
2022-04-19 11:30:00
Alkermes plc announced that it commenced binding arbitration proceedings in respect of two license agreements with Janssen Pharmaceutica N.V. ("Janssen"), a subsidiary of Johnson & Johnson. Under these agreements, Janssen received access and rights to Alkermes' small particle pharmaceutical compound technology, known as NanoCrystal® Technology, which enabled a number of successful products, such as INVEGA SUSTENNA®, INVEGA TRINZA®, INVEGA HAFYERA® and CABENUVA®. Janssen partially terminated the agreements in the United States effective as of February 2022. The purpose of the arbitration is to settle, among other things, whether, notwithstanding its partial termination of the agreements, Janssen has a continuing obligation to pay royalties on sales in the United States of products developed under the agreements. Janssen has refused to pay any royalties required by the agreements in the United States since the effective date of the partial terminations. Alkermes strongly disagrees with Janssen's position and contends that it continues to owe royalties. Alkermes remains committed to enforcing its contractual rights and addressing any unauthorized use of its intellectual property. Following receipt of the notices of partial termination, Alkermes triggered dispute resolution provisions in the license agreements. The company has engaged with Janssen in an effort to come to a mutually agreeable settlement. No resolution has been achieved. Alkermes remains open to a mutually agreeable resolution. Under the agreements, the arbitration will be conducted pursuant to the Institute for Conflict Prevention and Resolution (CPR) Rules for Non-Administered Arbitration before a panel of three arbitrators. The arbitration will be confidential, subject to the parties' disclosure obligations under applicable law. Other than pursuant to these obligations, Alkermes does not intend to comment or provide additional information regarding the arbitration until an order on the merits or other material order is issued in the arbitration or the arbitration is otherwise concluded.
Alkermes plc Proposes Amendments to the Articles of Association
2022-04-18 13:24:00
Alkermes plc announced at the extraordinary general meeting of shareholders to be held on May 13, 2022 that the company proposed amendments to the Articles of Association to provide for plurality voting for contested elections.
Alkermes plc, Special/Extraordinary Shareholders Meeting, May 13, 2022
2022-04-18 13:24:00
Alkermes plc, Special/Extraordinary Shareholders Meeting, May 13, 2022, at 12:30 Coordinated Universal Time. Location: Connaught House, 1 Burlington Road Dublin-4 Ireland Agenda: To consider certain amendments to the Company’s Articles of Association to provide for plurality voting for contested elections; and to transact such other business as may properly come before the meeting and any adjournments or postponements thereof.
Alkermes plc Provides Information to Shareholders
2022-04-18 09:24:00
On April 18, 2022, Alkermes plc announced that it scheduled the extraordinary general meeting of shareholders on May 13, 2022. In addition, the Company recommended the shareholders to vote for its proposal for approval of the proposed amendments to Company’s Articles of Association.
Alkermes plc Presents at Bank of America 2022 Healthcare Conference, May-10-2022
2022-03-22 05:03:00
Alkermes plc Presents at Bank of America 2022 Healthcare Conference, May-10-2022 . Venue: Encore Hotel, 3121 Las Vegas Blvd. S, Las Vegas, Nevada, United States. Speakers: Blair C. Jackson, Executive VP & COO, Iain Michael Brown, Senior VP & CFO, Richard F. Pops, Chairman & CEO, Sandra Coombs, Senior Vice President of Corporate Affairs & Investor Relations.
Bank of America Corporation, Bank of America 2022 Healthcare Conference, May 10, 2022 through May 13, 2022
2022-02-17 10:42:00
Bank of America Corporation, Bank of America 2022 Healthcare Conference, May 10, 2022 through May 13, 2022. Venue: Encore Hotel, 3121 Las Vegas Blvd. S, Las Vegas, Nevada, United States.
Tranche Update on Alkermes plc (NasdaqGS:ALKS)'s Equity Buyback Plan announced on November 21, 2007.
2022-02-16 09:13:00
From October 1, 2021 to December 31, 2021, the company has repurchased 0 shares, representing 0% for $0 million. With this, the company has completed the repurchase of 8,866,342 shares, representing 8.68% for $114 million under the buyback announced on November 21, 2007.
Jefferies LLC, 2022 Jefferies Global Healthcare Conference, Jun 08, 2022 through Jun 10, 2022
2022-02-14 21:00:00
Jefferies LLC, 2022 Jefferies Global Healthcare Conference, Jun 08, 2022 through Jun 10, 2022. Venue: Marriott Marquis, New York City, New York, United States.
Alkermes plc Announces Positive Topline Results From ENLIGHTEN-Early Phase 3b Study of LYBALVI® in Patients Early in Illness
2022-02-08 12:00:00
Alkermes plc announced positive topline results from ENLIGHTEN-Early, a phase 3b study that evaluated the effect of LYBALVI® (olanzapine and samidorphan) compared to olanzapine on body weight in young adult patients (ages 16 to 39; mean age: 26 years) with schizophrenia, schizophreniform disorder or bipolar I disorder who were early in their illness. The study met its pre-specified primary endpoint, as patients treated with LYBALVI experienced statistically significantly less weight gain than patients treated with olanzapine at Week 12 (mean percent change from baseline body weight: 6.77% for olanzapine vs. 4.91% for LYBALVI, p=0.012). Consistent with the ENLIGHTEN-2 pivotal study,1 a numerical difference in average weight gain between treatment arms was observed early in treatment and continued to separate through the study's prespecified primary endpoint. LYBALVI is approved for the treatment of adults with schizophrenia, and for the treatment of adults with bipolar I disorder, as a maintenance monotherapy or for the acute treatment of manic or mixed episodes as monotherapy or an adjunct to lithium or valproate. The study employed a hierarchical testing methodology for four pre-specified secondary endpoints. The first secondary endpoint did not achieve the pre-specified significance level, which precluded the assessment of statistical significance of the subsequent endpoints in the hierarchy. A numerical difference was observed between treatment arms across all secondary endpoints in favor of LYBALVI. Results of the secondary endpoints were as follows: The proportion of patients who gained 10% or more of their baseline body weight at three months was 30.4% for olanzapine vs. 21.9% for LYBALVI (p=0.075). The proportion of patients who gained 7% or more of their baseline body weight at three months was 44.8% for olanzapine vs. 33.1% for LYBALVI. The mean change from baseline in waist circumference at three months was 3.90 cm for patients treated with olanzapine vs. 2.99 cm for patients treated with LYBALVI. Treatment with LYBALVI was associated with improvements in symptoms of schizophrenia and bipolar I disorder over three months, as measured by the Clinical Global Impression of Severity (CGI-S) scale (mean change from baseline in CGI-S score of -0.82). The safety profile of LYBALVI was consistent with previous studies. Overall, 63.5% of patients receiving LYBALVI and 63.3% of patients receiving olanzapine reported adverse events while on treatment. The most common adverse events reported for the LYBALVI treatment group were weight gain, somnolence and increased alanine aminotransferase and for the olanzapine treatment group were weight gain, somnolence and increased waist circumference. Serious adverse events occurred in 3.8% of LYBALVI patients and 3.7% of olanzapine patients during the treatment period. A majority of patients in both treatment groups completed the three-month study (78.2% of patients who received LYBALVI and 74.9% of patients who received olanzapine).
The Goldman Sachs Group, Inc., Goldman Sachs 43rd Annual Global Healthcare Conference, Jun 13, 2022 through Jun 16, 2022
2022-02-08 07:31:00
The Goldman Sachs Group, Inc., Goldman Sachs 43rd Annual Global Healthcare Conference, Jun 13, 2022 through Jun 16, 2022. Venue: Terranea Resort, Rancho Palos Verdes, California, United States.
American Society Of Clinical Oncology, Inc., the 2022 ASCO Annual Meeting, Jun 03, 2022 through Jun 07, 2022
2021-12-10 06:32:00
American Society Of Clinical Oncology, Inc., The 2022 ASCO Annual Meeting, Jun 03, 2022 through Jun 07, 2022. Venue: McCormick Place, Chicago, Illinois, United States.
Alkermes plc Presents at 4th Annual Evercore ISI HealthCONx Virtual Conference, Dec-02-2021 10:30 AM
2021-11-24 21:00:00
Alkermes plc Presents at 4th Annual Evercore ISI HealthCONx Virtual Conference, Dec-02-2021 10:30 AM.
Alkermes plc Announces Appointment of Cato T. Laurencin to Its Board of Directors
2021-11-19 12:00:00
Alkermes plc announced the appointment of a new independent director, Cato T. Laurencin, M.D., Ph.D., to the company's Board of Directors. Dr. Laurencin is a distinguished university professor, award-winning engineer, orthopaedic surgeon, scientist, administrator, and pioneer in the field of regenerative engineering. Dr. Laurencin is actively involved in mentoring and social justice initiatives and has been widely recognized for his work promoting diversity and excellence in science and addressing health disparities. He currently serves as a professor of multiple disciplines at the University of Connecticut (UConn). He is the University Professor and Van Dusen Distinguished Endowed Professor of Orthopaedic Surgery, Professor of Chemical and Biomolecular Engineering, Professor of Materials Science and Engineering and Professor of Biomedical Engineering. He is the Chief Executive Officer of The Connecticut Convergence Institute for Translation in Regenerative Engineering at UConn.
Alkermes plc Presents at Access Insights Conference 2021, Nov-15-2021
2021-11-12 05:15:00
Alkermes plc Presents at Access Insights Conference 2021, Nov-15-2021 . Speakers: Joe Puma, Senior Director, Corporate Accounts.
Alkermes plc Announces First Subject Dosed in Phase 1 Study of ALKS 1140 for the Treatment of Neurodegenerative and Neurological Disorders
2021-11-11 12:00:00
Alkermes plc announced dosing of the first subject in a phase 1 study evaluating the safety and tolerability of ALKS 1140 in healthy adults. ALKS 1140 is a novel, investigational CoREST-selective (co-repressor of repressor element-1 silencing transcription factor) HDAC (histone deacetylase) inhibitor candidate for the treatment of neurodegenerative and neurological disorders. ALKS 1140 is designed to increase functional synaptic connections and synaptic integrity in the brain. The primary objectives of this first-in-human, phase 1, two-part study are to assess the safety and tolerability of single (part 1) and multiple (part 2) ascending oral doses of ALKS 1140 in healthy adults. The study is also designed to characterize the pharmacokinetic and pharmacodynamic profile of ALKS 1140. The study is expected to enroll up to 80 healthy volunteers at a clinical study site in Australia.
Alkermes plc Presents at Stifel 2021 Virtual Healthcare Conference, Nov-16-2021 09:20 AM
2021-11-09 20:52:00
Alkermes plc Presents at Stifel 2021 Virtual Healthcare Conference, Nov-16-2021 09:20 AM. Venue: New York, New York, United States.
Alkermes Announces Receipt of Notices of Partial Termination from Janssen Pharmaceutica
2021-11-08 21:05:00
Alkermes plc announced that it received notices of partial termination (the "Notices") in respect of two license agreements with Janssen Pharmaceutica N.V. ("Janssen"), a subsidiary of Johnson & Johnson and, under these agreements, a licensee and recipient of Alkermes' nanoparticulate formulation technology, known as NanoCrystal® technology. The terminations impact know-how royalties related to sales of long-acting paliperidone products, such as INVEGA SUSTENNA® and INVEGA TRINZA®, and other products in the United States. Pursuant to the agreements, the partial termination is to become effective three months from the date of receipt of the Notices. Janssen maintains that it has not utilized, and does not utilize, Alkermes' NanoCrystal technology licensed under the agreements. Alkermes strongly disagrees with Janssen's position and will explore all options at its disposal to enforce its contractual rights and address any unauthorized use of its intellectual property.
Alkermes plc - Special Call
2021-11-08 00:00:00
Alkermes plc - Special Call
The International Society For Affective Disorders, International Society for Affective Disorders (ISAD) Conference, Nov 03, 2021 through Nov 04, 2021
2021-10-29 11:00:00
The International Society For Affective Disorders, International Society for Affective Disorders (ISAD) Conference, Nov 03, 2021 through Nov 04, 2021.
Psych Congress , Psych Congress 2021, Oct 29, 2021 through Nov 11, 2021
2021-10-29 11:00:00
Psych Congress , Psych Congress 2021, Oct 29, 2021 through Nov 11, 2021.
Alkermes plc Presents at Psych Congress 2021, Oct-29-2021
2021-10-29 11:00:00
Alkermes plc Presents at Psych Congress 2021, Oct-29-2021 .
Alkermes plc Presents at International Society for Affective Disorders (ISAD) Conference, Nov-03-2021
2021-10-29 11:00:00
Alkermes plc Presents at International Society for Affective Disorders (ISAD) Conference, Nov-03-2021 .
Neuroscience Education Institute, Neuroscience Education Institute (NEI) Congress, Nov 04, 2021 through Nov 07, 2021
2021-10-29 11:00:00
Neuroscience Education Institute, Neuroscience Education Institute (NEI) Congress, Nov 04, 2021 through Nov 07, 2021. Venue: Colorado Sprigns, Colorado, United States.
Alkermes plc Presents at Neuroscience Education Institute (NEI) Congress, Nov-04-2021
2021-10-29 11:00:00
Alkermes plc Presents at Neuroscience Education Institute (NEI) Congress, Nov-04-2021 . Venue: Colorado Sprigns, Colorado, United States.
Alkermes Initiates ARTISTRY-7 Phase 3 Trial of Nemvaleukin Alfa in Patients with Platinum-Resistant Ovarian Cancer
2021-10-26 11:00:00
Alkermes plc announced the initiation of ARTISTRY-7, a global phase 3, open-label, randomized trial evaluating the anti-tumor activity and safety of intravenously administered (IV) nemvaleukin alfa (nemvaleukin), in combination with pembrolizumab, compared to investigator's choice chemotherapy, in patients with platinum-resistant ovarian cancer. Nemvaleukin, Alkermes' lead immuno-oncology candidate, is a novel, investigational, engineered interleukin-2 (IL-2) variant immunotherapy. As previously announced, ARTISTRY-7 is being conducted in collaboration with MSD (a tradename of Merck & Co. Inc. Kenilworth, NJ, USA), which is providing KEYTRUDA® (pembrolizumab) for the study. In addition, Alkermes is working with The GOG Foundation Inc. (GOG) and the European Network of Gynaecological Oncological Trial groups (ENGOT) to conduct the study. The U.S. Food and Drug Administrationrecently granted Fast Track designation to nemvaleukin in combination with pembrolizumab for the treatment of platinum-resistant ovarian cancer. ARTISTRY-7 is a global phase 3, open-label, randomized study designed to evaluate the anti-tumor activity and safety of IV nemvaleukin in combination with pembrolizumab compared to investigator's choice chemotherapy, with additional nemvaleukin and pembrolizumab monotherapy arms, in patients with platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal cancer. The primary endpoint of ARTISTRY-7 is progression-free survival as assessed by the investigator, based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1. Additional endpoints include objective response rate, overall survival, disease control rate, duration of response, time to response, cancer antigen-125 response, pharmacokinetics (PK)/pharmacodynamics (PD) and safety. The study is expected to enroll approximately 376 patients. Patients will be randomized to one of four treatment arms to receive nemvaleukin and pembrolizumab combination therapy, pembrolizumab monotherapy, nemvaleukin monotherapy, or investigator's choice chemotherapy.
Alkermes plc Receives FDA Fast Track Designation for Nemvaleukin Alfa in Combination with Pembrolizumab for the Treatment of Platinum-Resistant Ovarian Cancer
2021-10-25 11:00:00
Alkermes plc announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to nemvaleukin alfa (nemvaleukin), the company's novel, investigational, engineered interleukin-2 (IL-2) variant immunotherapy, in combination with pembrolizumab, an anti-PD-1 antibody, for the treatment of platinum-resistant ovarian cancer. The FDA previously granted Fast Track designation and Orphan Drug designation to nemvaleukin for the treatment of mucosal melanoma. Fast Track is an FDA process designed to facilitate the development, and expedite the review, of potential therapies that seek to treat serious conditions and fill an unmet medical need. A drug candidate that receives Fast Track designation is eligible for more frequent communication with the FDA throughout the drug development process and a rolling and/or priority review of its marketing application if relevant criteria are met.
Alkermes plc, Q3 2021 Earnings Call, Oct 27, 2021
2021-10-20 20:00:00
Alkermes plc, Q3 2021 Earnings Call, Oct 27, 2021
Alkermes plc to Report Q3, 2021 Results on Oct 27, 2021
2021-10-20 20:00:00
Alkermes plc announced that they will report Q3, 2021 results on Oct 27, 2021
Alkermes Announces Commercial Availability of Lybalvi® for the Treatment of Schizophrenia and Bipolar I Disorder
2021-10-18 11:00:00
Alkermes plc announced that LYBALVI® (olanzapine and samidorphan) is now available by prescription in the United States (U.S.) for the treatment of adults with schizophrenia, and for the treatment of adults with bipolar I disorder, as a maintenance monotherapy or for the acute treatment of manic or mixed episodes as monotherapy or an adjunct to lithium or valproate. LYBALVI is a once-daily, oral atypical antipsychotic composed of olanzapine, an established antipsychotic agent, and samidorphan, a new chemical entity. In the ENLIGHTEN clinical development program, LYBALVI demonstrated antipsychotic efficacy, safety and tolerability. Results from the ENLIGHTEN program's pivotal ENLIGHTEN-1 study in schizophrenia, which demonstrated antipsychotic efficacy compared to placebo, and ENLIGHTEN-2 study in schizophrenia, which demonstrated LYBALVI's effect on weight gain compared to olanzapine, as well as their respective 52-week extension studies, have been published in peer-reviewed journals. The U.S. Food and Drug Administration (FDA) approved LYBALVI under the 505(b)(2) regulatory pathway based on data from 27 clinical studies, including 18 studies evaluating LYBALVI and nine studies evaluating samidorphan alone, and the FDA's findings of safety and effectiveness of olanzapine in the treatment of bipolar I disorder and schizophrenia.
Alkermes plc Presents at Cantor Global Healthcare 2021 Conference, Sep-29-2021 08:40 AM
2021-09-22 20:00:00
Alkermes plc Presents at Cantor Global Healthcare 2021 Conference, Sep-29-2021 08:40 AM. Venue: New York, United States.
Alkermes plc Presents at Citi’s 16th Annual BioPharma Virtual Conference, Sep-09-2021 08:50 AM
2021-09-01 18:36:00
Alkermes plc Presents at Citi’s 16th Annual BioPharma Virtual Conference, Sep-09-2021 08:50 AM. Venue: New York, United States. Speakers: Blair C. Jackson, Executive VP & COO, Iain Michael Brown, Senior VP & CFO.
Evercore Inc., 4th Annual Evercore ISI HealthCONx Virtual Conference, Nov 29, 2021 through Dec 03, 2021
2021-08-24 20:29:00
Evercore Inc., 4th Annual Evercore ISI HealthCONx Virtual Conference, Nov 29, 2021 through Dec 03, 2021.
Alkermes plc Presents at European Society for Medical Oncology Virtual Congress 2021, Sep-16-2021
2021-08-23 12:06:00
Alkermes plc Presents at European Society for Medical Oncology Virtual Congress 2021, Sep-16-2021 . Venue: Paris Expo Porte de Versailles, Paris, France.
Alkermes plc Presents at Pharma Marketing USA, Nov-08-2021
2021-08-05 10:11:00
Alkermes plc Presents at Pharma Marketing USA, Nov-08-2021 . Speakers: Christopher Nugent, Associate Director, Digital Marketing & Strategy.
Reuters Events, Pharma Marketing USA, Nov 08, 2021 through Nov 10, 2021
2021-08-05 03:58:00
Reuters Events, Pharma Marketing USA, Nov 08, 2021 through Nov 10, 2021.
Alkermes plc Revises Earnings Guidance for the Full Year 2021
2021-07-28 11:06:00
Alkermes plc revises earnings guidance for the full year 2021. The company now expects Total Revenue of $1,145 million– $1,185 million, GAAP Net Loss of $60 million– $90 million or $0.37 to $0.56 per share against previous forecast of Total Revenue of $1,100 million– $1,170 million, GAAP Net Loss of $85 million– $125 million or $0.53 to $0.78 per share.
Tranche Update on Alkermes plc (NasdaqGS:ALKS)'s Equity Buyback Plan announced on November 21, 2007.
2021-07-28 09:16:00
From April 1, 2021 to June 30, 2021, the company has repurchased 0 shares, representing 0% for $0 million. With this, the company has completed the repurchase of 8,866,342 shares, representing 8.68% for $114 million under the buyback announced on November 21, 2007.
Alkermes plc has filed a Shelf Registration in the amount of $193.12 million.
2021-07-28 00:00:00
Alkermes plc has filed a Shelf Registration in the amount of $193.12 million. Security Name: Ordinary Shares Securities Offered: 8,000,000 Transaction Features: ESOP Related Offering
Informa plc, Independent Medical Education & Grants Summit, Sep 21, 2021 through Sep 23, 2021
2021-07-22 01:55:00
Informa plc, Independent Medical Education & Grants Summit, Sep 21, 2021 through Sep 23, 2021.
Alkermes plc Presents at Independent Medical Education & Grants Summit, Sep-21-2021 through Sep-23-2021
2021-07-22 01:55:00
Alkermes plc Presents at Independent Medical Education & Grants Summit, Sep-21-2021 through Sep-23-2021. Presentation Date & Speakers: Sep-21-2021, Stephen Lind, Director Medical Affairs, Grants, Sponsorships, and Corporate Funding, Stephen Lind, Director, Medical Affairs, Grants, Sponsorships & Corporate Funding, Stephen Lind, Director, Medical Affairs, Grants, Sponsorships and Corporate Funding. Sep-22-2021, Stephen Lind, Director, Medical Affairs, Grants, Sponsorships & Corporate Funding, Stephen Lind, Director, Medical Affairs, Grants, Sponsorships and Corporate Funding. Sep-23-2021, Stephen Lind, Director, Medical Affairs, Grants, Sponsorships and Corporate Funding.
Alkermes plc, Q2 2021 Earnings Call, Jul 28, 2021
2021-07-21 20:00:00
Alkermes plc, Q2 2021 Earnings Call, Jul 28, 2021
Alkermes plc to Report Q2, 2021 Results on Jul 28, 2021
2021-07-21 20:00:00
Alkermes plc announced that they will report Q2, 2021 results on Jul 28, 2021
Stifel, Nicolaus & Company, Incorporated, Stifel 2021 Virtual Healthcare Conference, Nov 15, 2021 through Nov 17, 2021
2021-07-08 08:44:00
Stifel, Nicolaus & Company, Incorporated, Stifel 2021 Virtual Healthcare Conference, Nov 15, 2021 through Nov 17, 2021. Venue: New York, New York, United States.
Alkermes Presents New Data Analysis on Healthcare Resource Use Among Veterans with Alcohol Dependence
2021-06-30 11:00:00
Alkermes plc announced the presentation of new health economics and outcomes research related to healthcare resource use among veterans with alcohol dependence at the 2021 Research Society on Alcoholism Scientific Meeting/International Society for Biomedical Research on Alcoholism Conference, which took place virtually June 19-23, 2021. The company presented results from a retrospective, observational study using data from the Veterans Health Administration database, which includes healthcare encounters, treatments and laboratory tests at VHA facilities. The study assessed treatment patterns and HRU among 3,665 patients diagnosed with alcohol dependence who were treated with VIVITROL. In the study, VIVITROL treatment for alcohol dependence was associated with decreases in inpatient care and increases in outpatient care during the one-year period following initiation of treatment with VIVITROL, compared to the one-year period before VIVITROL treatment initiation. Specifically: During the baseline period, defined as the one year before VIVITROL initiation, 61.5% of patients had at least one inpatient admission, and 39.8 % of patients had an emergency department visit. During the follow up period, defined as one year after VIVITROL initiation, 37.8% of patients had at least one inpatient admission and 35.4% of patients had an emergency department visit. These HRU changes may reflect a possible transition to less resource-intensive care for veterans initiating VIVITROL. The generalizability of these results to the U.S. population may be limited. The company previously presented data from another retrospective, observational study using the same VHA database at the Association of Military Surgeons of the United States, The Society of Federal Health Professionals, Annual Meeting in December 2020. That study was one of the first studies to provide insights into the patient journey among veterans from alcohol dependence diagnosis to VIVITROL initiation and beyond. Patients studied had extensive health care use and carried a high burden of chronic disease, including hypertension (40.5%), chronic pain (10.8%), and diabetes (9.7%). In addition, a majority had diagnoses for mental health comorbidities, such as depression (74.1%), non-alcohol/opioid substance use disorder (66.3%), and post-traumatic stress syndrome (52.9%). Key findings included: Although 25 % of patients initiated VIVITROL within 60 days of diagnosis, the average time from initial diagnosis to VIVITROL initiation was analogous to 13.6 months. While many of the patients studied (75.8%) received oral naltrexone prior to initiating VIVITROL, 22.0% initiated VIVITROL as first-line medication. Additionally, about half of the patients studied (46.6%) did not initiate other alcohol dependence medications during the study period following initiation of treatment with VIVITROL.
Fundamental Summary
Alkermes published its Q1 report on 2022-04-27 with positive results, but no significant factors particularly remarkable relative to its peers. It is highly likely that the company will be mostly tethered to market performance and sector movements for the near term. We gave Alkermes a 69 rating and a HOLD recommendation.
Alkermes reported earnings results for the first quarter ended March 31, 2022. For the first quarter, the company reported revenue was USD 278.55 million compared to USD 251.43 million a year ago. Net loss was USD 35.9 million compared to USD 22.42 million a year ago. Basic loss per share from continuing operations was USD 0.22 compared to USD 0.14 a year ago.
Business Description
Alkermes, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; VIVITROL for the treatment of alcohol and prevention of opioid dependence; RISPERDAL CONSTA for the treatment of schizophrenia and bipolar I disorder; INVEGA SUSTENNA for the treatment of schizophrenia and schizoaffective disorder; XEPLION, INVEGA TRINZA, and TREVICTA to treat schizophrenia and schizoaffective; and VUMERITY for the treatment of relapsing forms of multiple sclerosis in adults, including clinically isolated syndrome, relapsing-remitting and active secondary progressive diseases. The company is also developing LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder; and nemvaleukin alfa, an engineered fusion protein to expand tumor-killing immune cells and to avoid the activation of immunosuppressive cells. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. Alkermes was founded in 1987 and is headquartered in Dublin, Ireland.
Sector Overview
Alkermes is included in the Biotechnology according to GICS (global industry classification standard). The Biotechnology industry, which is part of the Health Care sector, includes companies primarily engaged in R&D, manufacturing, and/or marketing of products based on genetic analysis and genetic engineering. Alkermes's industry and sector affiliation are expected to negatively affect their likelihood to overperform the market in the upcoming period, as other sectors appear more likely to benefit from the macroeconomic environment we see now.
Fundamental Highlights
| Parameter | Value | Change | Score | |
|---|---|---|---|---|
| Return on Equity | -5.8 | -31.2% | 81 | |
| Net Cashflow | 77.5 | 20.0% | 89 | |
| Capital Expenditure | -27.7 | 0.1% | 76 | |
| Asset Turnover | 0.6 | 5.4% | 80 | |
| Free Cashflow | 0.9 | 91.3% | 95 |
* All values are TTM
The below chart reflects Alkermes's birds-eye view on its performance with respect to its peers, the company's fillings as reported or to a similar industry, market cap, and country of origin. While Alkermes's peer average final assessment score stands on 69.0, Alkermes's score is 69.
- ALKS
- Peers average
Technical Analysis
When trying to optimize the timing of an investment, it's critical to analyze whether the stock looks overbought or oversold, and in which direction the momentum is moving. Alkermes's stock is now priced above its 5-day, 50-day, and 200-day moving average, while its MACD (moving average convergence divergence) indicates that the stock's price movement momentum is strengthening. Historically, this is a positive setup in the near, medium, and long-term. In particular, many institutional investors keep close watch of the 200-day moving average. Meanwhile, looking at the Stochastic Oscillator and RSI (relative strength index), Alkermes's stock indicates that it's likely oversold. Overall, these technical indicators signal positive upward momentum. Therefore, this stock received a cumulative TA (technical analysis) score of 78.
5D MA
29.5
50D MA
28.62
200D MA
26.86
MACD
0.24
RSI
0.88
STOCH
100.0
Balance Sheet Analysis
Two metrics jump up as the most significant positive drivers of the balance sheet strength in Alkermess recent report: Book Value Factors and Assets. Alkermes publishes solid book value factor metrics in this report. Price to book ratio (P/B) now sits at 4.5 and represents a 33.5% change from the previous report. Their industry-leading book value factors momentum reinforces an expectation for future positive momentum for their stock price going forward. The company's book value factors component, therefore, received a grade of 71. Also, The company's assets section could set high expectations for Alkermes's future attractiveness, as they went to 1977.8, which is a -2.3% change from the last period. This performance is interesting in comparison to its peers and competitors. Consequently, their asset movement received a grade of 66. That said, one metric, Equity, stood out as strongly negative. Alkermes management produced disappointing equity metrics this period, which stood at 1075.4, representing a -3.3% change. This parameter often affects companies in the same industry and market capitalization by up to 7.3%. Their equity metrics appear unremarkable relative to their peers. Therefore, their equity movement component earned a score of 46. Therefore, we scored its balance sheet a 62.
| Parameter | Value | Change | Score |
|---|---|---|---|
| Assets | 1,977.8 | -2.3% | 66 |
| Liabilities | 902.5 | -1.0% | 63 |
| Price to Book | 4.5 | 33.5% | 71 |
| Cash & Equivalents | 282.6 | -16.3% | 54 |
| Equity | 1,075.4 | -3.3% | 46 |
The below chart describes Alkermes's performance as reflected on its balance sheet with respect to its peers. While Alkermes received a balance sheet score of 62, the average of its peers stands on 67.0.
- ALKS
- Peers average
| Name | Market Cap | Liabilities Movement | Asset Change | Equity/Intangibles Adjustments | Cash & Equivalents | Book Value Momentum | Balance Sheet | mc_sort | Hidden |
|---|---|---|---|---|---|---|---|---|---|
| Amgen Inc. | 130.1B | 72 | 68 | 86 | 53 | 62 | 69 | 0 | 1 |
| Gilead Sciences, Inc. | 78.0B | 48 | 63 | 61 | 52 | 62 | 57 | 1 | 1 |
| Vertex Pharmaceuticals Incorporated | 70.6B | 69 | 69 | 58 | 84 | 92 | 78 | 2 | 1 |
| Regeneron Pharmaceuticals, Inc. | 64.0B | 48 | 65 | 52 | 86 | 81 | 67 | 3 | 1 |
| BioNTech SE | 34.0B | 75 | 69 | 64 | 97 | 73 | 75 | 4 | 1 |
| Seagen Inc. | 32.9B | 59 | 68 | 55 | 43 | 66 | 61 | 5 | 1 |
| Biogen Inc. | 29.7B | 57 | 72 | 92 | 50 | 76 | 76 | 6 | 1 |
| Alnylam Pharmaceuticals, Inc. | 17.2B | 50 | 66 | 46 | 44 | 61 | 54 | 7 | 1 |
| Incyte Corporation | 16.8B | 71 | 72 | 95 | 82 | 79 | 83 | 8 | 1 |
| BioMarin Pharmaceutical Inc. | 15.4B | 55 | 75 | 54 | 77 | 74 | 70 | 9 | 1 |
| United Therapeutics Corporation | 10.6B | 61 | 74 | 58 | 60 | 88 | 76 | 10 | 1 |
| Neurocrine Biosciences, Inc. | 9.3B | 67 | 69 | 55 | 51 | 78 | 68 | 11 | 1 |
| Exelixis, Inc. | 6.7B | 53 | 66 | 57 | 84 | 81 | 70 | 12 | 1 |
| Sarepta Therapeutics, Inc. | 6.5B | 68 | 69 | 49 | 41 | 58 | 58 | 13 | 1 |
| Halozyme Therapeutics, Inc. | 6.3B | 59 | 68 | 65 | 72 | 85 | 74 | 14 | 1 |
| Ionis Pharmaceuticals, Inc. | 5.4B | 59 | 68 | 58 | 43 | 67 | 62 | 15 | 1 |
| Ascendis Pharma A/S | 5.2B | 51 | 70 | 85 | 94 | 54 | 68 | 16 | 1 |
| Cytokinetics, Incorporated | 4.1B | 49 | 79 | 42 | 76 | 62 | 64 | 17 | 1 |
| Novavax, Inc. | 4.0B | 61 | 67 | 52 | 77 | 99 | 77 | 18 | 1 |
| Mirati Therapeutics, Inc. | 3.8B | 53 | 66 | 57 | 48 | 42 | 50 | 19 | 1 |
| Natera, Inc. | 3.6B | 73 | 65 | 43 | 95 | 42 | 54 | 20 | 1 |
| Arrowhead Pharmaceuticals, Inc. | 3.4B | 72 | 71 | 63 | 65 | 73 | 71 | 21 | 1 |
| PTC Therapeutics, Inc. | 2.8B | 57 | 61 | 80 | 49 | 37 | 51 | 22 | 1 |
| Insmed Incorporated | 2.4B | 49 | 65 | 45 | 46 | 63 | 55 | 23 | 1 |
| ACADIA Pharmaceuticals Inc. | 2.3B | 83 | 65 | 55 | 91 | 55 | 63 | 24 | 1 |
| BioCryst Pharmaceuticals, Inc. | 1.9B | 46 | 67 | 46 | 50 | 62 | 55 | 25 | 1 |
| ChemoCentryx, Inc. | 1.8B | 72 | 77 | 47 | 53 | 52 | 61 | 26 | 1 |
| Ironwood Pharmaceuticals, Inc. | 1.8B | 49 | 68 | 87 | 67 | 63 | 68 | 27 | 1 |
| Myriad Genetics, Inc. | 1.5B | 51 | 62 | 51 | 43 | 57 | 52 | 28 | 1 |
| Agios Pharmaceuticals, Inc. | 1.2B | 50 | 66 | 52 | 38 | 48 | 50 | 29 | 1 |
| IVERIC bio, Inc. | 1.1B | 50 | 67 | 46 | 48 | 48 | 50 | 30 | 1 |
| FibroGen, Inc. | 1.0B | 79 | 87 | 49 | 82 | 56 | 73 | 31 | 1 |
| Syndax Pharmaceuticals, Inc. | 1.0B | 85 | 68 | 41 | 55 | 55 | 58 | 32 | 1 |
| ImmunoGen, Inc. | 946.1M | 52 | 67 | 64 | 61 | 48 | 56 | 33 | 1 |
| Enanta Pharmaceuticals, Inc. | 922.8M | 51 | 86 | 45 | 38 | 49 | 60 | 34 | 1 |
| Deciphera Pharmaceuticals, Inc. | 914.0M | 56 | 71 | 38 | 82 | 63 | 61 | 35 | 1 |
| Anavex Life Sciences Corp. | 767.1M | 50 | 67 | 50 | 75 | 66 | 61 | 36 | 1 |
| Sangamo Therapeutics, Inc. | 600.0M | 59 | 64 | 47 | 45 | 46 | 48 | 37 | 1 |
| AnaptysBio, Inc. | 586.3M | 85 | 63 | 41 | 37 | 51 | 52 | 38 | 1 |
| Geron Corporation | 566.2M | 69 | 72 | 37 | 59 | 62 | 60 | 39 | 1 |
| Mersana Therapeutics, Inc. | 449.1M | 75 | 68 | 39 | 82 | 52 | 58 | 40 | 1 |
| Inovio Pharmaceuticals, Inc. | 416.9M | 56 | 66 | 38 | 54 | 40 | 46 | 41 | 1 |
| Arbutus Biopharma Corporation | 388.2M | 86 | 65 | 61 | 48 | 55 | 60 | 42 | 1 |
| Intercept Pharmaceuticals, Inc. | 386.3M | 46 | 68 | 57 | 41 | 61 | 57 | 43 | 1 |
| Anika Therapeutics, Inc. | 322.7M | 76 | 68 | 63 | 64 | 65 | 64 | 44 | 1 |
| Lexicon Pharmaceuticals, Inc. | 321.6M | 48 | 68 | 51 | 43 | 51 | 51 | 45 | 1 |
| Precigen, Inc. | 299.1M | 81 | 85 | 61 | 72 | 48 | 73 | 46 | 1 |
| bluebird bio, Inc. | 288.7M | 48 | 67 | 42 | 38 | 57 | 50 | 47 | 1 |
| Rigel Pharmaceuticals, Inc. | 187.5M | 53 | 67 | 51 | 90 | 63 | 62 | 48 | 1 |
| MacroGenics, Inc. | 184.6M | 53 | 64 | 61 | 37 | 39 | 47 | 49 | 1 |
| Exact Sciences Corporation | 7.2B | 57 | 58 | 45 | 42 | 52 | 47 | 50 | 1 |
| Amicus Therapeutics, Inc. | 3.0B | 52 | 64 | 58 | 66 | 56 | 56 | 51 | 1 |
| CureVac N.V. | 2.6B | 49 | 64 | 75 | 52 | 52 | 57 | 52 | 1 |
| Fate Therapeutics, Inc. | 2.4B | 63 | 70 | 54 | 39 | 45 | 53 | 53 | 1 |
| Abgenix Inc. | 2.1B | 81 | 57 | 86 | 92 | 45 | 67 | 54 | 1 |
| Xenon Pharmaceuticals Inc. | 1.9B | 48 | 69 | 53 | 45 | 70 | 61 | 55 | 1 |
| Iovance Biotherapeutics, Inc. | 1.7B | 52 | 74 | 72 | 87 | 45 | 63 | 56 | 1 |
| Xencor, Inc. | 1.6B | 53 | 78 | 60 | 40 | 67 | 67 | 57 | 1 |
| Emergent BioSolutions Inc. | 1.6B | 48 | 62 | 87 | 48 | 61 | 61 | 58 | 1 |
| Dynavax Technologies Corporation | 1.5B | 52 | 69 | 54 | 38 | 76 | 63 | 59 | 1 |
| Ligand Pharmaceuticals Incorporated | 1.5B | 75 | 63 | 61 | 49 | 52 | 56 | 60 | 1 |
| Aurinia Pharmaceuticals Inc. | 1.4B | 51 | 67 | 59 | 41 | 47 | 52 | 61 | 1 |
| Veracyte, Inc. | 1.4B | 64 | 68 | 54 | 66 | 51 | 57 | 62 | 1 |
| Sierra Oncology, Inc. | 1.3B | 62 | 71 | 52 | 97 | 97 | 80 | 63 | 1 |
| Celldex Therapeutics, Inc. | 1.3B | 48 | 69 | 61 | 44 | 57 | 57 | 64 | 1 |
| CareDx, Inc | 1.2B | 54 | 67 | 52 | 39 | 51 | 52 | 65 | 1 |
| Vericel Corporation | 1.1B | 51 | 65 | 56 | 53 | 61 | 57 | 66 | 1 |
| Avid Bioservices, Inc. | 959.5M | 75 | 61 | 61 | 58 | 72 | 67 | 67 | 1 |
| MannKind Corporation | 957.2M | 79 | 59 | 50 | 40 | 64 | 57 | 68 | 1 |
| Merus N.V. | 941.6M | 59 | 68 | 50 | 83 | 81 | 70 | 69 | 1 |
| Sorrento Therapeutics, Inc. | 747.5M | 89 | 71 | 50 | 97 | 73 | 74 | 70 | 1 |
| Amarin Corporation plc | 734.5M | 51 | 65 | 58 | 72 | 51 | 55 | 71 | 1 |
| Catalyst Pharmaceuticals, Inc. | 707.1M | 52 | 69 | 70 | 77 | 86 | 75 | 72 | 1 |
| Northwest Biotherapeutics, Inc. | 682.9M | 65 | 63 | 48 | 38 | 86 | 65 | 73 | 1 |
| Organogenesis Holdings Inc. | 612.1M | 59 | 66 | 56 | 66 | 60 | 60 | 74 | 1 |
| CTI BioPharma Corp. | 603.6M | 84 | 70 | 37 | 92 | 37 | 54 | 75 | 1 |
| Vanda Pharmaceuticals Inc. | 598.8M | 82 | 70 | 47 | 89 | 56 | 64 | 76 | 1 |
| Eagle Pharmaceuticals, Inc. | 546.4M | 83 | 70 | 73 | 46 | 79 | 75 | 77 | 1 |
| Immatics N.V. | 538.7M | 56 | 70 | 84 | 95 | 73 | 76 | 78 | 1 |
| Agenus Inc. | 520.5M | 73 | 62 | 37 | 55 | 60 | 54 | 79 | 1 |
| Radius Health, Inc. | 499.8M | 50 | 64 | 50 | 44 | 59 | 54 | 80 | 1 |
| Vaxart, Inc. | 440.0M | 69 | 67 | 47 | 56 | 47 | 53 | 81 | 1 |
| Affimed N.V. | 415.0M | 56 | 66 | 63 | 56 | 47 | 54 | 82 | 1 |
| ADMA Biologics, Inc. | 396.6M | 74 | 68 | 49 | 77 | 72 | 68 | 83 | 1 |
| MiMedx Group, Inc. | 391.5M | 53 | 66 | 42 | 57 | 37 | 45 | 84 | 1 |
| Albireo Pharma, Inc. | 362.9M | 48 | 65 | 42 | 58 | 62 | 54 | 85 | 1 |
| AVEO Pharmaceuticals, Inc. | 337.5M | 76 | 68 | 61 | 78 | 60 | 66 | 86 | 1 |
| Zymeworks Inc. | 324.7M | 77 | 69 | 70 | 90 | 43 | 62 | 87 | 1 |
| Heron Therapeutics, Inc. | 314.6M | 84 | 65 | 48 | 43 | 58 | 58 | 88 | 1 |
| Silence Therapeutics plc | 313.4M | 58 | 71 | 69 | 63 | 59 | 66 | 89 | 1 |
| AC Immune SA | 299.8M | 84 | 64 | 47 | 53 | 75 | 68 | 90 | 1 |
| Viridian Therapeutics, Inc. | 293.2M | 56 | 72 | 44 | 37 | 76 | 65 | 91 | 1 |
| Sutro Biopharma, Inc. | 245.5M | 82 | 69 | 56 | 66 | 49 | 61 | 92 | 1 |
| Chimerix, Inc. | 178.4M | 48 | 63 | 46 | 95 | 40 | 49 | 93 | 1 |
| DermTech, Inc. | 165.3M | 76 | 72 | 51 | 52 | 43 | 56 | 94 | 1 |
| Gelesis Holdings, Inc. | 111.5M | 47 | 76 | 48 | 76 | 98 | 78 | 95 | 1 |
| Brooklyn ImmunoTherapeutics, Inc. | 31.8M | 37 | 71 | 45 | 39 | 55 | 49 | 96 | 1 |
| INSYS Therapeutics, Inc. | 3.2M | 48 | 70 | 44 | 90 | 37 | 43 | 97 | 1 |
Income Statement Analysis
Alkermes appears likely to maintain its strong income statement metrics and momentum going forward. In this filing, Alkermes reported a return on equity (ROE) ratio of -5.8, which represents a change of -31.2%. These numbers show that management has successfully encouraged growth while managing ROE and ROA metrics, especially relative to their peers. Consequently, their return factors received a grade of 81. Also, Alkermes did an excellent job managing its revenue efficiency this past period. Alkermes's revenue efficiency is 1200.9 according to the metrics in the current filing, which represents a 2.3% change from the previous report. This characteristic can affect companies in the same industry and market capitalization by up to 13.1%. Their impressive revenue efficiency is even more impressive relative to its peers and competitors in the current market. The company's revenue efficiency, therefore, received a grade of 69. On the other hand, EBITDA, jumped out as looking problematic. Alkermes's EBIDTA now sits at 57.7 and represents -16.3% change from the last reporting period. This parameter coud affect companies in the same industry and market capitalization by up to 24.4%. The company's EBITDA metrics highlight a difficult overall financial situation, which may, unfortunately, continue moving forward unless management makes significant changes. Therefore, their EBITDA component earned a score of 55. Consequently, their income statement earned a rank of 62.
| Parameter | Value | Change | Score |
|---|---|---|---|
| EBITDA | 57.7 | -16.3% | 55 |
| Total Revenues | 1,200.9 | 2.3% | 69 |
| Return on Equity | -5.8 | -31.2% | 81 |
The below chart describes Alkermes's performance as reflected on its income statement with respect to its peers. While Alkermes received a income statement score of 62 , the average of its peers stands on 70.0.
- ALKS
- Peers average
| Name | Market Cap | Revenue Momentum | Earning Movement | Return Factors Momentum | Income Statement | mc_sort | Hidden |
|---|---|---|---|---|---|---|---|
| Amgen Inc. | 130.1B | 74 | 75 | 64 | 78 | 0 | 1 |
| Gilead Sciences, Inc. | 78.0B | 78 | 71 | 52 | 73 | 1 | 1 |
| Vertex Pharmaceuticals Incorporated | 70.6B | 57 | 80 | 62 | 75 | 2 | 1 |
| Regeneron Pharmaceuticals, Inc. | 64.0B | 67 | 74 | 66 | 74 | 3 | 1 |
| BioNTech SE | 34.0B | 41 | 89 | 75 | 79 | 4 | 1 |
| Seagen Inc. | 32.9B | 54 | 65 | 70 | 62 | 5 | 1 |
| Biogen Inc. | 29.7B | 90 | 57 | 73 | 70 | 6 | 1 |
| Alnylam Pharmaceuticals, Inc. | 17.2B | 60 | 86 | 56 | 80 | 7 | 1 |
| Incyte Corporation | 16.8B | 59 | 77 | 60 | 73 | 8 | 1 |
| BioMarin Pharmaceutical Inc. | 15.4B | 72 | 81 | 65 | 82 | 9 | 1 |
| United Therapeutics Corporation | 10.6B | 57 | 91 | 54 | 82 | 10 | 1 |
| Neurocrine Biosciences, Inc. | 9.3B | 53 | 54 | 77 | 55 | 11 | 1 |
| Exelixis, Inc. | 6.7B | 54 | 91 | 54 | 81 | 12 | 1 |
| Sarepta Therapeutics, Inc. | 6.5B | 49 | 89 | 55 | 78 | 13 | 1 |
| Halozyme Therapeutics, Inc. | 6.3B | 53 | 84 | 85 | 82 | 14 | 1 |
| Ionis Pharmaceuticals, Inc. | 5.4B | 62 | 94 | 53 | 86 | 15 | 1 |
| Ascendis Pharma A/S | 5.2B | 38 | 68 | 46 | 54 | 16 | 1 |
| Cytokinetics, Incorporated | 4.1B | 95 | 50 | 73 | 66 | 17 | 1 |
| Novavax, Inc. | 4.0B | 41 | 89 | 54 | 75 | 18 | 1 |
| Mirati Therapeutics, Inc. | 3.8B | 76 | 55 | 78 | 64 | 19 | 1 |
| Natera, Inc. | 3.6B | 52 | 51 | 78 | 52 | 20 | 1 |
| Arrowhead Pharmaceuticals, Inc. | 3.4B | 38 | 92 | 53 | 76 | 21 | 1 |
| PTC Therapeutics, Inc. | 2.8B | 54 | 78 | 66 | 73 | 22 | 1 |
| Insmed Incorporated | 2.4B | 51 | 58 | 73 | 57 | 23 | 1 |
| ACADIA Pharmaceuticals Inc. | 2.3B | 72 | 49 | 80 | 58 | 24 | 1 |
| BioCryst Pharmaceuticals, Inc. | 1.9B | 41 | 74 | 72 | 66 | 25 | 1 |
| ChemoCentryx, Inc. | 1.8B | 97 | 57 | 71 | 73 | 26 | 1 |
| Ironwood Pharmaceuticals, Inc. | 1.8B | 70 | 79 | 61 | 79 | 27 | 1 |
| Myriad Genetics, Inc. | 1.5B | 89 | 93 | 57 | 96 | 28 | 1 |
| Agios Pharmaceuticals, Inc. | 1.2B | 99 | 64 | 54 | 75 | 29 | 1 |
| IVERIC bio, Inc. | 1.1B | 84 | 58 | 79 | 70 | 30 | 1 |
| FibroGen, Inc. | 1.0B | 48 | 74 | 63 | 67 | 31 | 1 |
| Syndax Pharmaceuticals, Inc. | 1.0B | 87 | 47 | 81 | 62 | 32 | 1 |
| ImmunoGen, Inc. | 946.1M | 40 | 73 | 71 | 64 | 33 | 1 |
| Enanta Pharmaceuticals, Inc. | 922.8M | 90 | 63 | 72 | 75 | 34 | 1 |
| Deciphera Pharmaceuticals, Inc. | 914.0M | 60 | 79 | 70 | 77 | 35 | 1 |
| Anavex Life Sciences Corp. | 767.1M | 84 | 69 | 60 | 75 | 36 | 1 |
| Sangamo Therapeutics, Inc. | 600.0M | 72 | 72 | 73 | 76 | 37 | 1 |
| AnaptysBio, Inc. | 586.3M | 97 | 50 | 77 | 68 | 38 | 1 |
| Geron Corporation | 566.2M | 89 | 67 | 73 | 78 | 39 | 1 |
| Mersana Therapeutics, Inc. | 449.1M | 37 | 54 | 72 | 47 | 40 | 1 |
| Inovio Pharmaceuticals, Inc. | 416.9M | 96 | 57 | 68 | 72 | 41 | 1 |
| Arbutus Biopharma Corporation | 388.2M | 37 | 82 | 53 | 67 | 42 | 1 |
| Intercept Pharmaceuticals, Inc. | 386.3M | 71 | 93 | 40 | 86 | 43 | 1 |
| Anika Therapeutics, Inc. | 322.7M | 63 | 80 | 62 | 77 | 44 | 1 |
| Lexicon Pharmaceuticals, Inc. | 321.6M | 98 | 48 | 82 | 69 | 45 | 1 |
| Precigen, Inc. | 299.1M | 57 | 87 | 59 | 79 | 46 | 1 |
| bluebird bio, Inc. | 288.7M | 99 | 91 | 61 | 96 | 47 | 1 |
| Rigel Pharmaceuticals, Inc. | 187.5M | 99 | 44 | 82 | 64 | 48 | 1 |
| MacroGenics, Inc. | 184.6M | 95 | 56 | 74 | 71 | 49 | 1 |
| Exact Sciences Corporation | 7.2B | 57 | 67 | 54 | 62 | 50 | 1 |
| Amicus Therapeutics, Inc. | 3.0B | 61 | 55 | 77 | 58 | 51 | 1 |
| CureVac N.V. | 2.6B | 45 | 83 | 71 | 74 | 52 | 1 |
| Fate Therapeutics, Inc. | 2.4B | 45 | 52 | 61 | 46 | 53 | 1 |
| Abgenix Inc. | 2.1B | 47 | 47 | 47 | 47 | 54 | 1 |
| Xenon Pharmaceuticals Inc. | 1.9B | 41 | 65 | 59 | 56 | 55 | 1 |
| Iovance Biotherapeutics, Inc. | 1.7B | 84 | 60 | 75 | 71 | 56 | 1 |
| Xencor, Inc. | 1.6B | 42 | 94 | 52 | 79 | 57 | 1 |
| Emergent BioSolutions Inc. | 1.6B | 91 | 51 | 77 | 66 | 58 | 1 |
| Dynavax Technologies Corporation | 1.5B | 51 | 69 | 77 | 67 | 59 | 1 |
| Ligand Pharmaceuticals Incorporated | 1.5B | 92 | 53 | 78 | 69 | 60 | 1 |
| Aurinia Pharmaceuticals Inc. | 1.4B | 38 | 81 | 68 | 70 | 61 | 1 |
| Veracyte, Inc. | 1.4B | 45 | 63 | 57 | 55 | 62 | 1 |
| Sierra Oncology, Inc. | 1.3B | 84 | 54 | 54 | 61 | 63 | 1 |
| Celldex Therapeutics, Inc. | 1.3B | 96 | 53 | 78 | 70 | 64 | 1 |
| CareDx, Inc | 1.2B | 61 | 44 | 82 | 50 | 65 | 1 |
| Vericel Corporation | 1.1B | 76 | 44 | 82 | 56 | 66 | 1 |
| Avid Bioservices, Inc. | 959.5M | 49 | 82 | 69 | 75 | 67 | 1 |
| MannKind Corporation | 957.2M | 95 | 48 | 56 | 61 | 68 | 1 |
| Merus N.V. | 941.6M | 48 | 60 | 59 | 54 | 69 | 1 |
| Sorrento Therapeutics, Inc. | 747.5M | 50 | 60 | 60 | 55 | 70 | 1 |
| Amarin Corporation plc | 734.5M | 95 | 44 | 82 | 63 | 71 | 1 |
| Catalyst Pharmaceuticals, Inc. | 707.1M | 48 | 88 | 58 | 77 | 72 | 1 |
| Northwest Biotherapeutics, Inc. | 682.9M | 43 | 90 | 65 | 79 | 73 | 1 |
| Organogenesis Holdings Inc. | 612.1M | 89 | 55 | 79 | 69 | 74 | 1 |
| CTI BioPharma Corp. | 603.6M | 84 | 50 | 62 | 59 | 75 | 1 |
| Vanda Pharmaceuticals Inc. | 598.8M | 89 | 46 | 81 | 62 | 76 | 1 |
| Eagle Pharmaceuticals, Inc. | 546.4M | 39 | 94 | 53 | 78 | 77 | 1 |
| Immatics N.V. | 538.7M | 37 | 93 | 53 | 77 | 78 | 1 |
| Agenus Inc. | 520.5M | 57 | 83 | 45 | 74 | 79 | 1 |
| Radius Health, Inc. | 499.8M | 94 | 71 | 68 | 82 | 80 | 1 |
| Vaxart, Inc. | 440.0M | 99 | 51 | 72 | 68 | 81 | 1 |
| Affimed N.V. | 415.0M | 95 | 49 | 75 | 66 | 82 | 1 |
| ADMA Biologics, Inc. | 396.6M | 43 | 65 | 62 | 57 | 83 | 1 |
| MiMedx Group, Inc. | 391.5M | 87 | 43 | 83 | 59 | 84 | 1 |
| Albireo Pharma, Inc. | 362.9M | 46 | 69 | 77 | 65 | 85 | 1 |
| AVEO Pharmaceuticals, Inc. | 337.5M | 38 | 89 | 54 | 74 | 86 | 1 |
| Zymeworks Inc. | 324.7M | 58 | 53 | 77 | 56 | 87 | 1 |
| Heron Therapeutics, Inc. | 314.6M | 61 | 60 | 75 | 62 | 88 | 1 |
| Silence Therapeutics plc | 313.4M | 83 | 64 | 69 | 72 | 89 | 1 |
| AC Immune SA | 299.8M | 83 | 61 | 65 | 70 | 90 | 1 |
| Viridian Therapeutics, Inc. | 293.2M | 55 | 50 | 63 | 53 | 91 | 1 |
| Sutro Biopharma, Inc. | 245.5M | 60 | 47 | 80 | 56 | 92 | 1 |
| Chimerix, Inc. | 178.4M | 99 | 50 | 62 | 65 | 93 | 1 |
| DermTech, Inc. | 165.3M | 49 | 48 | 78 | 52 | 94 | 1 |
| Gelesis Holdings, Inc. | 111.5M | 41 | 46 | 56 | 39 | 95 | 1 |
| Brooklyn ImmunoTherapeutics, Inc. | 31.8M | 83 | 49 | 92 | 61 | 96 | 1 |
| INSYS Therapeutics, Inc. | 3.2M | 97 | 48 | 63 | 70 | 97 | 1 |
Cash Flow Analysis
Overall, Alkermes's critical cash flow metrics appear to signal strong support and a high likelihood of positive growth going forward. Free cash flow numbers published by Alkermes were 0.9, which was a 91.3% change from the previous filing. Companies in the same industry and market capitalization are typically affected by this parameter by up to 2.6%. These free cash flow numbers show that management has executed well while generating cash flow and encouraging growth. Consequently, their free cash flow movement received a grade of 95. Also, Alkermes's management was effective in improving their net cash flow, which now sits at 77.5 and represents a 20.0% change from the previous report. This industry-leading net cash flow momentum should reinforce broader positive momentum for its's stock price going forward. Hence, its net cash flow earned a score of 89. That said, one metric, Capital Expenditure, stood out as particularly concerning. Alkermes's management was ineffective in materially improving CapEx, which now sits at -27.7 and represents a 0.1% change from the previous report. This performance is all the more uninspiring relative to their peers and competitors. Therefore, their CapEx movement component earned a score of 76. Because the company's management is doing an excellent job managing these critical metrics, the cash flow was given a score of 92.
| Parameter | Value | Change | Score |
|---|---|---|---|
| Net Cashflow | 77.5 | 20.0% | 89 |
| Capital Expenditure | -27.7 | 0.1% | 76 |
| Asset Turnover | 0.6 | 5.4% | 80 |
| Free Cashflow | 0.9 | 91.3% | 95 |
The below chart describes Alkermes's performance as reflected on its cash flow with respect to its peers. While Alkermes received a cash flow score of 92, the average of its peers stands on 72.0.
- ALKS
- Peers average
| Name | Market Cap | Cashflow Momentum | Free Cashflow Growth | Capital Expenditure Growth | Assets Factors Momentum | Cash Flow | mc_sort | Hidden |
|---|---|---|---|---|---|---|---|---|
| Amgen Inc. | 130.1B | 80 | 74 | 67 | 74 | 81 | 0 | 1 |
| Gilead Sciences, Inc. | 78.0B | 57 | 61 | 53 | 85 | 62 | 1 | 1 |
| Vertex Pharmaceuticals Incorporated | 70.6B | 64 | 75 | 80 | 71 | 71 | 2 | 1 |
| Regeneron Pharmaceuticals, Inc. | 64.0B | 69 | 86 | 64 | 66 | 73 | 3 | 1 |
| BioNTech SE | 34.0B | 73 | 97 | 50 | 52 | 72 | 4 | 1 |
| Seagen Inc. | 32.9B | 53 | 53 | 50 | 87 | 58 | 5 | 1 |
| Biogen Inc. | 29.7B | 58 | 54 | 90 | 73 | 66 | 6 | 1 |
| Alnylam Pharmaceuticals, Inc. | 17.2B | 82 | 80 | 70 | 89 | 85 | 7 | 1 |
| Incyte Corporation | 16.8B | 78 | 79 | 92 | 74 | 84 | 8 | 1 |
| BioMarin Pharmaceutical Inc. | 15.4B | 59 | 48 | 66 | 77 | 63 | 9 | 1 |
| United Therapeutics Corporation | 10.6B | 93 | 92 | 68 | 80 | 93 | 10 | 1 |
| Neurocrine Biosciences, Inc. | 9.3B | 63 | 43 | 54 | 74 | 63 | 11 | 1 |
| Exelixis, Inc. | 6.7B | 79 | 90 | 89 | 83 | 87 | 12 | 1 |
| Sarepta Therapeutics, Inc. | 6.5B | 85 | 89 | 95 | 87 | 93 | 13 | 1 |
| Halozyme Therapeutics, Inc. | 6.3B | 83 | 66 | 52 | 49 | 75 | 14 | 1 |
| Ionis Pharmaceuticals, Inc. | 5.4B | 88 | 96 | 60 | 86 | 89 | 15 | 1 |
| Ascendis Pharma A/S | 5.2B | 48 | 59 | 77 | 98 | 62 | 16 | 1 |
| Cytokinetics, Incorporated | 4.1B | 63 | 79 | 89 | 51 | 69 | 17 | 1 |
| Novavax, Inc. | 4.0B | 62 | 38 | 63 | 54 | 60 | 18 | 1 |
| Mirati Therapeutics, Inc. | 3.8B | 56 | 58 | 71 | 89 | 65 | 19 | 1 |
| Natera, Inc. | 3.6B | 52 | 54 | 56 | 84 | 58 | 20 | 1 |
| Arrowhead Pharmaceuticals, Inc. | 3.4B | 60 | 39 | 87 | 96 | 70 | 21 | 1 |
| PTC Therapeutics, Inc. | 2.8B | 72 | 53 | 54 | 83 | 72 | 22 | 1 |
| Insmed Incorporated | 2.4B | 79 | 80 | 61 | 89 | 82 | 23 | 1 |
| ACADIA Pharmaceuticals Inc. | 2.3B | 61 | 57 | 98 | 80 | 72 | 24 | 1 |
| BioCryst Pharmaceuticals, Inc. | 1.9B | 61 | 58 | 54 | 96 | 67 | 25 | 1 |
| ChemoCentryx, Inc. | 1.8B | 84 | 92 | 97 | 50 | 87 | 26 | 1 |
| Ironwood Pharmaceuticals, Inc. | 1.8B | 77 | 66 | 67 | 76 | 78 | 27 | 1 |
| Myriad Genetics, Inc. | 1.5B | 50 | 37 | 82 | 83 | 59 | 28 | 1 |
| Agios Pharmaceuticals, Inc. | 1.2B | 85 | 68 | 44 | 46 | 75 | 29 | 1 |
| IVERIC bio, Inc. | 1.1B | 64 | 67 | 44 | 71 | 64 | 30 | 1 |
| FibroGen, Inc. | 1.0B | 86 | 74 | 48 | 87 | 84 | 31 | 1 |
| Syndax Pharmaceuticals, Inc. | 1.0B | 50 | 41 | 74 | 78 | 57 | 32 | 1 |
| ImmunoGen, Inc. | 946.1M | 77 | 79 | 95 | 95 | 87 | 33 | 1 |
| Enanta Pharmaceuticals, Inc. | 922.8M | 58 | 47 | 84 | 83 | 66 | 34 | 1 |
| Deciphera Pharmaceuticals, Inc. | 914.0M | 87 | 79 | 95 | 91 | 94 | 35 | 1 |
| Anavex Life Sciences Corp. | 767.1M | 69 | 63 | 74 | 71 | 72 | 36 | 1 |
| Sangamo Therapeutics, Inc. | 600.0M | 85 | 78 | 93 | 83 | 91 | 37 | 1 |
| AnaptysBio, Inc. | 586.3M | 80 | 77 | 92 | 41 | 80 | 38 | 1 |
| Geron Corporation | 566.2M | 78 | 68 | 49 | 81 | 77 | 39 | 1 |
| Mersana Therapeutics, Inc. | 449.1M | 59 | 69 | 53 | 92 | 65 | 40 | 1 |
| Inovio Pharmaceuticals, Inc. | 416.9M | 67 | 67 | 92 | 44 | 71 | 41 | 1 |
| Arbutus Biopharma Corporation | 388.2M | 92 | 93 | 80 | 87 | 95 | 42 | 1 |
| Intercept Pharmaceuticals, Inc. | 386.3M | 87 | 95 | 98 | 89 | 96 | 43 | 1 |
| Anika Therapeutics, Inc. | 322.7M | 69 | 67 | 70 | 51 | 63 | 44 | 1 |
| Lexicon Pharmaceuticals, Inc. | 321.6M | 91 | 82 | 39 | 46 | 77 | 45 | 1 |
| Precigen, Inc. | 299.1M | 82 | 75 | 37 | 85 | 74 | 46 | 1 |
| bluebird bio, Inc. | 288.7M | 89 | 77 | 93 | 37 | 83 | 47 | 1 |
| Rigel Pharmaceuticals, Inc. | 187.5M | 42 | 40 | 46 | 40 | 41 | 48 | 1 |
| MacroGenics, Inc. | 184.6M | 70 | 53 | 54 | 46 | 65 | 49 | 1 |
| Exact Sciences Corporation | 7.2B | 53 | 45 | 80 | 46 | 56 | 50 | 1 |
| Amicus Therapeutics, Inc. | 3.0B | 81 | 80 | 71 | 87 | 85 | 51 | 1 |
| CureVac N.V. | 2.6B | 87 | 80 | 90 | 70 | 90 | 52 | 1 |
| Fate Therapeutics, Inc. | 2.4B | 64 | 52 | 55 | 48 | 61 | 53 | 1 |
| Abgenix Inc. | 2.1B | 66 | 53 | 45 | 59 | 58 | 54 | 1 |
| Xenon Pharmaceuticals Inc. | 1.9B | 82 | 77 | 87 | 92 | 89 | 55 | 1 |
| Iovance Biotherapeutics, Inc. | 1.7B | 77 | 66 | 69 | 69 | 77 | 56 | 1 |
| Xencor, Inc. | 1.6B | 96 | 95 | 70 | 95 | 98 | 57 | 1 |
| Emergent BioSolutions Inc. | 1.6B | 70 | 53 | 87 | 75 | 75 | 58 | 1 |
| Dynavax Technologies Corporation | 1.5B | 64 | 48 | 82 | 65 | 68 | 59 | 1 |
| Ligand Pharmaceuticals Incorporated | 1.5B | 86 | 93 | 51 | 78 | 84 | 60 | 1 |
| Aurinia Pharmaceuticals Inc. | 1.4B | 73 | 79 | 92 | 96 | 84 | 61 | 1 |
| Veracyte, Inc. | 1.4B | 90 | 95 | 46 | 46 | 82 | 62 | 1 |
| Sierra Oncology, Inc. | 1.3B | 47 | 77 | 38 | 71 | 52 | 63 | 1 |
| Celldex Therapeutics, Inc. | 1.3B | 69 | 63 | 67 | 54 | 69 | 64 | 1 |
| CareDx, Inc | 1.2B | 98 | 84 | 40 | 50 | 86 | 65 | 1 |
| Vericel Corporation | 1.1B | 64 | 46 | 59 | 73 | 65 | 66 | 1 |
| Avid Bioservices, Inc. | 959.5M | 80 | 38 | 40 | 50 | 66 | 67 | 1 |
| MannKind Corporation | 957.2M | 77 | 56 | 43 | 37 | 66 | 68 | 1 |
| Merus N.V. | 941.6M | 70 | 71 | 74 | 53 | 71 | 69 | 1 |
| Sorrento Therapeutics, Inc. | 747.5M | 48 | 63 | 61 | 52 | 52 | 70 | 1 |
| Amarin Corporation plc | 734.5M | 52 | 40 | 74 | 55 | 55 | 71 | 1 |
| Catalyst Pharmaceuticals, Inc. | 707.1M | 77 | 81 | 98 | 87 | 87 | 72 | 1 |
| Northwest Biotherapeutics, Inc. | 682.9M | 80 | 77 | 81 | 86 | 85 | 73 | 1 |
| Organogenesis Holdings Inc. | 612.1M | 76 | 76 | 63 | 55 | 75 | 74 | 1 |
| CTI BioPharma Corp. | 603.6M | 48 | 60 | 74 | 67 | 56 | 75 | 1 |
| Vanda Pharmaceuticals Inc. | 598.8M | 66 | 60 | 87 | 51 | 69 | 76 | 1 |
| Eagle Pharmaceuticals, Inc. | 546.4M | 63 | 40 | 97 | 92 | 73 | 77 | 1 |
| Immatics N.V. | 538.7M | 82 | 95 | 56 | 99 | 86 | 78 | 1 |
| Agenus Inc. | 520.5M | 57 | 43 | 52 | 77 | 58 | 79 | 1 |
| Radius Health, Inc. | 499.8M | 64 | 40 | 37 | 56 | 57 | 80 | 1 |
| Vaxart, Inc. | 440.0M | 72 | 56 | 53 | 38 | 65 | 81 | 1 |
| Affimed N.V. | 415.0M | 72 | 57 | 95 | 43 | 74 | 82 | 1 |
| ADMA Biologics, Inc. | 396.6M | 62 | 77 | 74 | 85 | 71 | 83 | 1 |
| MiMedx Group, Inc. | 391.5M | 46 | 48 | 97 | 86 | 60 | 84 | 1 |
| Albireo Pharma, Inc. | 362.9M | 59 | 68 | 41 | 95 | 63 | 85 | 1 |
| AVEO Pharmaceuticals, Inc. | 337.5M | 94 | 87 | 74 | 83 | 95 | 86 | 1 |
| Zymeworks Inc. | 324.7M | 52 | 65 | 45 | 83 | 57 | 87 | 1 |
| Heron Therapeutics, Inc. | 314.6M | 66 | 74 | 61 | 84 | 71 | 88 | 1 |
| Silence Therapeutics plc | 313.4M | 68 | 66 | 72 | 69 | 69 | 89 | 1 |
| AC Immune SA | 299.8M | 66 | 77 | 79 | 63 | 68 | 90 | 1 |
| Viridian Therapeutics, Inc. | 293.2M | 72 | 87 | 43 | 45 | 65 | 91 | 1 |
| Sutro Biopharma, Inc. | 245.5M | 83 | 67 | 64 | 50 | 74 | 92 | 1 |
| Chimerix, Inc. | 178.4M | 80 | 84 | 95 | 47 | 83 | 93 | 1 |
| DermTech, Inc. | 165.3M | 60 | 51 | 45 | 86 | 58 | 94 | 1 |
| Gelesis Holdings, Inc. | 111.5M | 64 | 90 | 92 | 98 | 80 | 95 | 1 |
| Brooklyn ImmunoTherapeutics, Inc. | 31.8M | 58 | 72 | 43 | 71 | 58 | 96 | 1 |
| INSYS Therapeutics, Inc. | 3.2M | 75 | 78 | 87 | 52 | 73 | 97 | 1 |
This report is intended for general guidance and information purposes only and under no circumstances is tailored to a specific factor or variable related to its reader or intended to be used or considered as financial or investment advice, a solicitation of any offer, a recommendation, or an offer to sell or buy any securities or other form of a financial asset. For the full disclaimer, click here.